HENDERSON: Indianapolis getting squeezed by suburbs
Indianapolis’ successful suburbs are rapidly surrounding the city. More important, tax and cultural shifts
are starting to drain Marion County.
Home » Search
Search Results
4,410 results for '\"eli lilly\"'
- Sort By
-
Date
- Any Time
- Past Day
- Past Week
- Past Month
- Past Year
-
Custom Date Range
Articles
Gun bills on fast track
Want to leave a gun in your car at work? Your employer’s policy may become irrelevant.
Company news
It’s the most famous rate hike in the country now. And that’s not good news for WellPoint Inc.
The Indianapolis-based health insurer’s California subsidiary will raise customers’ premiums by as much as 39
percent this year, according to the Associated Press. That alarmed President Obama, who is trying to resurrect his health
reform efforts. He cited the WellPoint rate hike in his Sunday interview with Katie Couric on CBS. "That’s a portrait
of the future if we don’t do something now," Obama said. Also, Obama’s health secretary, Kathleen Sebelius, fired
off a letter to WellPoint, demanding an explanation. The Obama administration has no authority in the matter, and the California
insurance department says it can do nothing about a rate hike unless WellPoint’s pricing violates state rules. But California
Insurance Commissioner Steve Poizner is hiring an outside actuary to make sure WellPoint’s rate hike won’t breach
a state threshold that no more than 30 percent of premiums pay for overhead and profits. WellPoint, in a statement, blamed
the rate hike on the weak economy, which has reduced WellPoint’s customer base by eliminating 7 million jobs, and on
ever-rising costs for medical care. The rate hike "highlights why we need sustainable health care reform to manage the
steadily rising costs of hospitals, drugs and doctors," the statement said.Eli Lilly and
Co. Chairman and CEO John C. Lechleiter received $16.4 million in total compensation last year, a 33.6-percent increase.
The rest of Lilly’s executive team got an average 25.4-percent pay hike. The majority of pay for the top five Lilly
executives came in the form of stock-based awards. But Lilly’s stock performance has been dismal the past two years. Indianapolis-based
Lilly faces a raft of patent expirations in the next five years that could sap more than half its current
revenue. On top of that, it has suffered numerous setbacks on bringing drugs to market. Therefore, investors
have sent Lilly’s stock price tumbling. Even counting Lilly’s substantial dividend, investors
suffered a 21-percent loss in value in 2008 and another 6-percent loss in 2009. By contrast, Lilly’s
profits have grown by double-digits each of the past two years.Dublin, Ohio-based
health care products distributor Cardinal Health LLC says it plans to cut more workers at its
Indianapolis distribution center, bringing the number of recent layoffs to 49. Cardinal Health notified the state on Feb.
3 that it laid off 37 workers at the end of January and plans to lay off 12 more effective April 3. The center is at 6812
Corporate Drive on the city’s northwest side. The cuts eliminated 44 warehouse-operations associates, two operations
managers, two warehouse supervisors and an assistant administrator. About 25 employees will be left at the facility after
the layoffs.Lilly awards pay increases to top executives
Eli Lilly and Co. CEO John Lechleiter’s total compensation increased $4.1 million in 2009.
Government reform, unemployment taxes chug through Legislature
Key measures cleared their chambers of origin by the Feb. 3 deadline.
Mississippi settles Zyprexa suit against Lilly for over $18M
Mississippi will receive $18.5 million from Indianapolis-based drugmaker Eli Lilly and Co. as part of a settlement over claims
the company promoted the anti-psychotic Zyprexa for ailments it was not federally approved to treat.Key business issues clear mid-session hurdle
The first half of a short session will close Wednesday, meaning bills must have passed out of either the House or Senate to
stay alive. Legislation regarding unemployment taxes and township-government reform easily met that deadline.People
Richard Shepperd is retiring as president and CEO of Bioanalytical Systems Inc., a
West Lafayette-based provider of clinical research services and equipment. Sheppard already surrendered his position as president,
and the company’s board named Anthony Chilton, the company’s chief operating officer, interim
president. The board said it would conduct a national search for a new CEO. Shepperd, 69, became CEO in September 2006 and
had agreed to stay no later than December 2009. During his tenure, Bioanalytical’s stock lost 85 percent
of its value.Dr. Michael Langley has joined Carmel-based Anson Group as a regulatory consultant.
Langley retired from Eli Lilly and Co., having served in many roles, including director of regulatory affairs and clinical
research.Dr. Shanna Bowman and Dr. Stacey Smith have joined County Line Pediatrics,
a new practice on South Emerson Avenue that’s part of St. Francis Medical Group. Both Bowman and Smith earned
their medical degrees at the Indiana University School of Medicine.The Indiana Health Industry Forum made Kristin
Jones its president and CEO after she had performed those jobs on an interim basis since 2008. Also, the health and
life sciences group named former Roche Diagnostics executive Joerg Schreiber chairman.Indy without Lilly, the 500?
An Indiana University prof thinks Indianapolis should anticipate a future without Indianapolis Motor Speedway, and a potentially
reduced Eli Lilly and Co.Q&A: Dr. Kristine Courtney
Dr. Kristine Courtney, Eli Lilly and Co.’s senior director of corporate health services, describes
how and why the company spent two years making its clinics some of the first to electronically swap patient records with
a local hospital database.City of Greenwood might fund launch of insulin maker
Greenwood-based Zimmerman Biotechnologies LLC hopes to become the first company in the United States to make generic insulin,
a long-awaited development in diabetes treatment. The Greenwood Common Council on Feb. 1 will consider an $8.4 million deal
that would finance construction of an insulin factory, as well as help Zimmerman with FDA-approval and equipment expenses.Health care reform will go on regardless of federal government
Massachusetts’ election of a Republican senator has put health reform legislation on life support. But for the health
care industry, reform is a reality that isn’t going to die.Lilly shares trade down after fourth-quarter profits falls
Analysts worry about dive in already paltry sales of new blood thinner Effient
Lilly’s profits fall, miss analyst expectations
The Indianapolis-based drugmaker says a weaker dollar depressed earnings in the fourth quarter compared with a year ago.
Company news
The Indiana University School of Medicine in Indianapolis will be one of 12 sites for a clinical trial
of a potentially groundbreaking treatment for autism. New York-based Curemark LLC has developed an ingestible powder designed
to help patients digest protein. The drug is the product of research by Curemark founder Dr. Joan Fallon, who found that many
autistic children lack enzymes to digest protein, meaning their bodies cannot produce the amino acids crucial in brain development.
If it proves effective against autism, the powder, called CA-MT, would be the first treatment to reverse the underlying causes
of autism.Hopes rose Tuesday that Eli Lilly and Co. and its partner Amylin Pharmaceuticals Inc.
will win approval of their new version of diabetes treatment Byetta. That’s because the U.S. Food and Drug Administration
on Monday approved a Byetta rival, Victoza, developed by Denmark-based Novo Nordisk A/S. Victoza is a once-daily shot, compared
with the twice-daily Byetta. But Indianapolis-based Lilly and San Diego-based Amylin have asked the FDA to approve a once-weekly
version of Byetta, which would be the most convenient for patients. Analysts expect sales of once-weekly Byetta to reach as
high as $2 billion by 2015, which would be split by Lilly and Amylin. Sales of twice-daily Byetta last year were on pace to
reach about $790 million. What’s been holding up Victoza and the once-weekly Byetta have been regulator concerns about
patients developing inflammation of the pancreas while taking the drugs. The FDA required Victoza’s label to warn about
pancreatitis as well as use in patients at risk for a rare thyroid cancer. Those warnings were milder than many analysts had
feared. One analyst expects the FDA to make a decision on once-weekly Byetta by March 5.Warsaw-based Symmetry
Medical Inc. will manufacture implants, instruments and cases for OrthoPediatrics Corp., another
Warsaw-based company that makes orthopedic implants for children. Symmetry expects to bring in $3 million in revenue from
the deal this year. Symmetry also will receive fees for inventory management, warehousing and supply-chain management services.
The agreement will last for five years.Lilly looks to autoimmune drugs
Two local researchers show why Eli Lilly and Co. and its peers are interested in developing medicines to treat automimmune
diseases: The costs of treating them are growing twice as fast as the prescription drug market.Health care reform dead; long live reform
Massachusetts’ election of a Republican senator has put health reform legislation on life support. But for the health
care industry, reform is a reality that isn’t going to die.Lilly shares get boost from OK of rival’s drug
Shares of Lilly and partner Amylin rose on hopes that their new version of Byetta will be approved following U.S. regulators’
clearance of a similar drug.Indianapolis deals in 2009 ranged from $4.6 billion to $70
WellPoint’s sale of its NextRx unit was the largest deal in the Indianapolis area in 2009.